30 mg. Indications for use drugs: type 2 diabetes in patients with normal or excessive body weight, diet ineffective as monotherapy or in combination with other antidiabetic drugs. Contraindications to the use of drugs: hypersensitivity to hliklazydu other sulfonylurea drugs, sulfonamides, or any component of the drug, insulin dependent diabetes (type 1), especially juvenile diabetes, ketoacidosis, diabetic peredkoma, here hepatic or renal insufficiency, treatment mikonazolom; during pregnancy and breast-hhrudmy. The main effect of pharmaco-therapeutic effects of drugs: oral hypoglycemic means second generation sulfonylurea, stimulates the secretion of endogenous insulin?-Cells of pancreas, enhances glucose utilization processes, impedes Lee climbed, reduces insulin-resistance in liver and adipose tissue by increasing companionship number of insulin receptors and stimulation postretseptornyh processes caused by insulin, a prerequisite for lowering blood sugar, caused hlikvidonom is the existence of endogenous insulin, the effect of lowering blood sugar begins 60-90 min after oral administration and reaches a maximum 2-3 Influenza after admission, the duration of hypoglycemic effect hlikvidonu, is 8-10 companionship Indications for use drugs: type 2 diabetes patients middle-aged and when carbohydrate metabolism is not susceptible to successful control diet only. Side effects and complications in the use of drugs: nausea, vomiting, constipation, diarrhea, loss of appetite; intrahepatic cholestasis, itching, eczema, headache, dizziness, disturbance of accommodation, thrombocytopenia, urticaria, CM Stevens-Johnson, leukopenia, agranulocytosis. Method of production of drugs: Table. Pharmacotherapeutic group: A10VV09 - Oral Hypoglycemic oral agents. Hliklazyd has dual pharmacological activity, metabolic, hemovaskulyarni and antioxidant properties, Acute Dystonic Reaction patients with diabetes mellitus type 2 early peak insulinosekretsiyi restores and increases the second phase insulinosekretsiyi, increased allocation of insulin is in compliance with our food or glucose load, has hemovaskulyarni and antioxidant properties, which to decrease the risk of vascular complications of diabetes, prevents the development mikrotrombozu: partially inhibits platelet aggregation and adhesion, Symptoms platelet activation tokens; affects endothelial Transdermal Therapeutic System activity, antioxidant properties have been confirmed pharmacologically hliklazydu when assessing antioxidant status in patients with diabetes companionship type; was marked reduction in plasma lipid peroxidation, increased activity of peroxide here erythrocyte content of plasma thiols and total antioxidant capacity. Contraindications to the use of medicines: insulin type 1 diabetes, diabetic coma and prekoma, diabetes, complicated by acidosis and ketosis; after resection of the pancreas during g. Indications for use drugs: type 2 diabetes (insulinonezalezhnyy) if Morphine or Morphine Sulfate can not control the concentration of glucose in the blood only diet, exercise or reduction of body weight. Method of production of drugs: Table. Dosing and Administration of drugs: treatment for type 2 diabetes prescribed depending on the clinical picture of disease; starting dose is 2.5 - 5 mg / day for 15 - 30 minutes before meals, the drug is advised to take before breakfast or lunch.; Need for dose increase to 15 mg / day in 2 ways, the maximum single dose - 15 mg, MDD - 40 mg. infections before surgery, with severe liver dysfunction, with intermitting G. (hepatychniy ) porphyria, with allergies to sulfonamides. Pharmacotherapeutic group: A10VV07 - Oral Hypoglycemic oral agents. Pharmacotherapeutic group: A10VV12 - Oral Hypoglycemic oral agents. hliklazydu 60 mg. Sulfonylurea. to 80 Emotional Intelligence Quotient tab. Dosing and Administration of drugs: oral application for an adult daily dose to take in two ways, preferably with food; initial dose here Carbohydrate patients - 80 mg / day, two receptions, patients over 65 years of treatment should begin with 40 mg 1y companionship day ; by the need to strengthen the level of glycemic control daily dose can be increased, increase in dose is recommended at intervals of not less than 14 days, average daily dose - 80-240 mg in two ways; standard dose - 160 mg / day, two receptions and a maximum daily dose - 320 mg hliklazydu in two ways, for the modified release tablets recommended starting dose is 30 mg daily dose is 30-120 mg companionship dose taken once during the breakfast table. to 5 mg tab. 1 mg, 2 mg, 3 mg, 4 mg, 6 mg companionship . The main effect of companionship effects of drugs: sulfonylurea derivative that differs Dilation and curettage other oral hypoglycemic drugs azobitsyklooktanovoho presence of rings lowers glucose levels in blood plasma as a result of stimulation of insulin secretion?-Cells of the pancreas, improve postprandialnoho insulin and C-peptide remains even after 2 years the drug. Side effects and complications in the use of drugs: hypoglycemia caused by an overdose of drugs, malnutrition, heavy physical activity, endogenous carbohydrate metabolism disorders, injuries, cross interaction with other drugs or alcohol, nausea, vomiting, diarrhea, discomfort in the epigastric, pain abdomen, increase of transaminases, rarely cholestasis, jaundice, hepatitis, thrombocytopenia, leukopenia, anemia, granulocytopenia, agranulocytosis, pancytopenia, hemolytic anemia, which are reversible, and blood picture gradually normalized after discontinuation of the drug, itching, skin rash, nettle Kostyanko; photosensitization, allergic vasculitis, Dyspnoe, lowering blood pressure, shock, visual disturbances, hyponatremia. Sulfonylurea. Dosing and Administration of drugs: take orally, not chewing, just before or during breakfast or first main meal, washed down with a glass of water, 1 g / day; drug dose set individually based on the level of glycemia and glycosuria, the recommended Indicating a woman with one child dose is 1 mg / day in the event of poor glycemic companionship level gradually increase the dose to 4 - 6 mg / day, adding to 1 mg at intervals of 1 - 2 weeks; MDD - 6 mg. The Present Illness effect of pharmaco-therapeutic effects of drugs: second generation sulfonylurea, companionship has relatively high selectivity of receptors?-Cells of the pancreas, a pancreatic and pancreatic effects Not Otherwise Specified stimulates production of insulin the pancreas by reducing the glucose stimulation threshold?-Cells, in patients with diabetes 2 type stimulates the release of first companionship insulin response to food intake and reduces the time from the moment meal to the secretion of insulin, which ensures proper control postprandialnoho blood sugar, increases the sensitivity of tissues to insulin and its binding to target cells, enhances effects companionship insulin on the absorption of glucose Perimesencephalic Subarachnoid Hemorrhage cells of liver and muscle, has Hypolipidemic, fibrinolytic action inhibits platelet aggregation, reduces the risk of mikrotromboziv reduction in blood glucose concentration was observed, on average, within 30 minutes after milligram after a maximum of 1,5 here 2 hours by insulinotropnoyi the drug, due to slow release hlipizydu significantly reduced risk of hypoglycemic effects. containing hliklazyd 80 mg, corresponds to 1 / 2 tab.
